Pre-made Bentracimab benchmark antibody ( Whole mAb, anti-AR-C124910XX therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-059

Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti-blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3] It is not commercially available.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-059-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody
INN Name Bentracimab
TargetAR-C124910XX
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5alb:HL
99% SI StructureNone
95-98% SI Structure5alc:HL
Year Proposed2020
Year Recommended2021
CompaniesMedImmune;AstraZeneca;PhaseBio
Conditions Approvedna
Conditions ActiveHaemorrhage (reversal of effects of ticagrelor)
Conditions Discontinuedna
Development Techna